Navigation Links
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
Date:5/29/2008

- Fifth cohort of MAD study supports continued development in

treatment-experienced patients -

BRISBANE, Calif., May 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin) in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotype 1 infection.

InterMune also reported that results from the only cohort of treatment-experienced patients in its Phase 1b multiple-ascending-dose (MAD) clinical trial of ITMN-191 given as monotherapy support continued development of the compound in treatment-experienced patients. InterMune expects to submit results from all dose cohorts in the MAD study for possible presentation at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Dan Welch, Chairman and Chief Executive Officer of InterMune, said, "After having recently announced excellent safety and very competitive reductions in serum HCV RNA levels following monotherapy of ITMN-191 in treatment-naive chronic hepatitis C patients, we are pleased to announce the start of our very important 14-day triple combination study of ITMN-191 plus Pegasys and ribavirin, also in treatment-naive patients." He continued, "We are also pleased to report that ITMN-191 given as monotherapy to treatment-experienced patients demonstrated a safety profile and viral kinetic performance that support the continued development of ITMN-191 in this patient population. Based on the monotherapy results to date, we and our partner Roche are planning the develop
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Oct. 24, 2014 Best Practices designed ... leaders with a forum for sharing insights about ... developed a mechanism for creating and sharing solutions ... key findings from the Medical Affairs Consortium survey. ... analysis for the first roundtable of the 2014-2015 ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
(Date:10/22/2014)... RPh, of Vernak Farms Pharmacy in Skaneateles, ... Roentsch Scholarship by the Professional Compounding Centers of America ... during PCCA,s International Seminar, held October 8-10, ... pharmacist and PCCA member who embodies the innovative and ... pharmacist in the compounding community. George ...
Breaking Medicine Technology:Strong Participation in Best Practices' Medical Affairs Consortium Survey 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2
... YORK, Sept. 23 Reportlinker.com announces that a ... catalogue: Genzyme Corporation: PharmaVitae Profile ... Introduction This analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
... Calif., Sept. 23 Preclinical data of a ... blood pressure) was presented Tuesday, September 21st, at ... Washington, DC, by Christopher D. Owens, MD, MSc, ... Endovascular Surgery, University of California, San Francisco. The ...
Cached Medicine Technology:Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 2Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 3Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 4Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 5Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 6Reportlinker Adds Genzyme Corporation: PharmaVitae Profile 7Promising New Therapy for Drug-Resistant Hypertension Presented at Interventional Cardiology Meeting in Washington, D.C. 2
(Date:10/22/2014)... At a time when the national concussion ... at all levels, the UPMC Sports Medicine Concussion ... where two powerful messages are lost: Concussions can be ... full recoveries every day. , In striving to shift ... research, UPMC and the Concussion Program are unveiling the ...
(Date:10/22/2014)... Isabel Healthcare will participate in ... Conference on October 22-24 in Las Vegas, NV. Jason ... panel discussion on Technology in Health Professions Education – ... diagnostic decision support tool and clinical education platform designed ... and clinical learners. The Isabel tools help clinicians broaden ...
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... Pass, OR (PRWEB) October 22, 2014 ... Southern California’s fresh water supply runs dangerously low, Southern ... change. Southern Oregon’s rivers, despite the lowest mountain snow ... even in late summer and early autumn.* That was ... authors of the new book “Hiking Southern Oregon,” during ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
Breaking Medicine News(10 mins):Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2
... University of Michigan Medical School and MedImmune, the global ... to work together on a broad range of projects. ... one of the nation,s top medical research institutions together ... of biologic therapies. UMMS and MedImmune scientists ...
... and subsequent left-ventricular function are significantly different based on the ... of its kind study in humans, published online Nov. 17 ... to the heart occurs when individuals have a heart attack ... size in rodents following ischemia and reperfusion exhibited a circadian ...
... SUNDAY, Nov. 20 (HealthDay News) -- Holiday foods and ... Americans with gastroesophageal reflux disease (GERD), but there are ... experts advise. GERD occurs when a faulty valve ... flow back into the esophagus. Symptoms of GERD include ...
... drug believed to prevent dysfunction of mitochondria, the ... appears to slow symptom progression in the neurodegenerative ... a phase 2 trial of dexpramipexole are receiving advance ... of the study were presented at the 2009 International ...
... SATURDAY, Nov. 19 (HealthDay News) -- Eating certain foods ... after you,ve used an at-home whitening kit or had ... who have had good results with either dentist-directed or ... keep the teeth white after bleaching," Dr. Raymond Garrison, ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Nov. ... more likely to lie to strangers when they,re communicating via ... face-to-face. "It,s not news that we lie. What,s new ... Mattitiyahu Zimbler, a graduate student and senior researcher at the ...
Cached Medicine News:Health News:U-M Medical School and MedImmune join forces to accelerate search for new therapies 2Health News:Severity of heart attack is dependent on the time of day 2Health News:Holiday Foods May Trigger GERD Symptoms 2Health News:Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial 2Health News:Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial 3Health News:Watch What You Eat After Teeth-Whitening, Expert Says 2Health News:People May Lie More Often in Emails, Instant Messages 2
Double-ended. Sharp and blunt 6.5 mm tips. Designated most popular model or size....
Octagonal handle. 3 mm wide....
Desmarres Retractor Size 4...
2.0 mm cup , straight shaft, Flat handle, length 125.0 mm....
Medicine Products: